Elanco today announced it has finalized the acquisition of Novartis Animal Health, creating a new global leader in animal health focused on delivering increased value and innovation to the industry.
The acquisition, announced in April, follows Elanco’s purchase of Lohmann Animal Health earlier in 2014. Both strategic investments position the company to offer a more diversified product offering and capabilities to help customers sustain and grow their businesses. This includes the flagship brands customers have come to expect from Elanco, but also a comprehensive portfolio of nearly 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes, food safety and more.
“Elanco’s acquisition of Novartis Animal Health brings together two strong companies with a passion for serving the customer,” said Rob Aukerman, president North American Commercial Operations for Elanco. “We will continue to offer the products our customers trust, while significantly investing in the development of new solutions to our customers’ greatest unmet needs.”
Going forward, Elanco will significantly increase investment in research and development, bringing greater breadth and depth to an already strong pipeline. The combined organization will have expanded capabilities and expertise with a broader portfolio of more than 100 product development projects focused on:
• protecting livestock from disease and parasites, improving animal well-being and reducing the environmental footprint of livestock production
• providing a broader set of solutions in areas such as enzymes, diagnostics, aquaculture and vaccines.
• enhancing care and extending quality of life of pets, while preventing disease and protecting from parasites
Elanco aims to help veterinarians help pets live longer, healthier lives, with pet ownership increasing as millions recognize the physical, social and emotional benefits of companionship. Elanco is also committed to helping producers around the world produce more food using fewer resources to meet the growing demand for animal protein while protecting the planet and well-being of animals.
“We’ll continually seek innovative ways we can support our customers’ business,” Aukerman said. “With increased technical services that combine our analytic and benchmarking tools with on-the-ground support, we’ll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business.”
The complete integration of the businesses will take time, but Elanco will strive to make the transition seamless. For the foreseeable future, business will continue in much the same way, including product ordering and customer support. Availability and access to products will continue uninterrupted. For more information about the transaction, visit www.elanco.com.
###
About Elanco
Elanco is a global innovation-driven company that develops and markets products to improve animal health, food animal production and companion animal care in nearly 70 countries. Elanco, a division of leading pharmaceutical company Eli Lilly and Company, employs approximately 7,000 people worldwide, with offices in more than 40 countries. Additional information about Elanco is available at www.elanco.com.